This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Klug, S. J. Articles by Muñoz, N. Search for Related Content PubMed PubMed Citation Articles by Klug, S. J. Articles by Muñoz, N.

TP53 Polymorphism, HPV Infection, and Risk of Cervical Cancer

University of Bielefeld, School of Public Health, 33501 Bielefeld, Germany [S. J. K.]; International Agency for Research on Cancer, Lyon, France [R. W., R. H., D. P-G., G. L., P. H., N. M.]; Centro de Investigación en Cáncer Maes-Heller, Lima, Peru [C. S., M. A., I. G., E. C.]; and Free University Hospital, Amsterdam, The Netherlands [J. M. M. W.]

The role of a polymorphism at position 72 of the tumor suppressor gene TP53 in the development of cervical cancer is not well established. The arginine variant of the p53 protein could be more susceptible to degradation by human papillomavirus (HPV) E6 protein than the protein containing proline. Recent studies show controversial results. We investigated a possible association between TP53 polymorphism and cervical cancer in a Peruvian population with high prevalence of HPV infection. HPV status and TP53 polymorphism were determined for 119 cases of invasive cervical cancer and 127 control women from Peru. HPV infection was detected by PCR of cervical cells or tumor biopsies. For determination of TP53 polymorphism, exon 4 of the TP53 gene was amplified by PCR, and DNA was subsequently subjected to restriction enzyme digest. Associations between TP53 polymorphism, HPV infection, and cervical cancer were assessed using logistic regression. Women homozygotes for arginine had a 2.2-fold increased risk (95% confidence interval: 0.6–7.6) for cervical cancer. The odds ratio for women heterozygotes for Arg/Pro was 3.5 (95% confidence interval: 0.9–14). Similarly increased risks were found when restricting analysis to HPV-positive women only. The distribution of TP53 genotypes in this Peruvian population was comparable with that found in Caucasians. Our results cannot rule out an association between the TP53 polymorphism at codon 72, HPV infection, and the etiology of cervical cancer.

This article has been cited by other articles:

				N. Jain, V. Singh, S. Hedau, S. Kumar, M. K. Daga, R. Dewan, N. S. Murthy, S. A. Husain, and B. C. Das Infection of Human Papillomavirus Type 18 and p53 Codon 72 Polymorphism in Lung Cancer Patients From India Chest, December 1, 2005; 128(6): 3999 - 4007. [Abstract] [Full Text] [PDF]

				S Mitra, C Misra, R K Singh, C K Panda, and S Roychoudhury Association of specific genotype and haplotype of p53 gene with cervical cancer in India J. Clin. Pathol., January 1, 2005; 58(1): 26 - 31. [Abstract] [Full Text] [PDF]

				A. Koushik, R. W. Platt, and E. L. Franco p53 Codon 72 Polymorphism and Cervical Neoplasia: A Meta-Analysis Review Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 11 - 22. [Abstract] [Full Text] [PDF]

				I. MABROUK, S. BACCOUCHE, R. EL-ABED, R. MOKDAD-GARGOURI, A. MOSBAH, S. SAID, J. DAOUD, M. FRIKHA, R. JLIDI, and A. GARGOURI No Evidence of Correlation between p53 Codon 72 Polymorphism and Risk of Bladder or Breast Carcinoma in Tunisian Patients Ann. N.Y. Acad. Sci., December 1, 2003; 1010(1): 764 - 770. [Abstract] [Full Text] [PDF]